Reply: Origins and Previous Applications of Causal-Benefit Models.
作者信息
Kohli-Lynch Ciaran, Thanassoulis George, Pencina Michael, Sehayek Daniel, Pencina Karol, Moran Andrew, Sniderman Allan D
机构信息
Northwestern University, Chicago, Illinois, USA.
Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre, Montreal, Quebec.
出版信息
JACC Adv. 2024 Jul 29;3(9):101090. doi: 10.1016/j.jacadv.2024.101090. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
Reply: Origins and Previous Applications of Causal-Benefit Models.
JACC Adv. 2024 Jul 29;3(9):101090. doi: 10.1016/j.jacadv.2024.101090. eCollection 2024 Sep.
2
Origins and Previous Applications of Causal-Benefit Models.
JACC Adv. 2024 Jul 29;3(9):101089. doi: 10.1016/j.jacadv.2024.101089. eCollection 2024 Sep.
3
Looking back on "causal thinking in the health sciences".
Annu Rev Public Health. 2000;21:101-19. doi: 10.1146/annurev.publhealth.21.1.101.
4
Hypertension of Developmental Origins: Consideration of Gut Microbiome in Animal Models.
Biomedicines. 2022 Apr 9;10(4):875. doi: 10.3390/biomedicines10040875.
5
The origins of causal perception: evidence from postdictive processing in infancy.
Cogn Psychol. 2008 Nov;57(3):262-91. doi: 10.1016/j.cogpsych.2008.02.003. Epub 2008 Jun 13.
6
Infants' representations of michottean triggering events.
Cognition. 2024 Sep;250:105844. doi: 10.1016/j.cognition.2024.105844. Epub 2024 Jun 8.
7
Causal Inference in Developmental Origins of Health and Disease (DOHaD) Research.
Annu Rev Psychol. 2016;67:567-85. doi: 10.1146/annurev-psych-122414-033352. Epub 2015 Oct 6.
8
Evolutionary history versus current causal role in the definition of disorder: reply to McNally.
Behav Res Ther. 2001 Mar;39(3):347-66. doi: 10.1016/s0005-7967(00)00070-x.
9
Animal Models for DOHaD Research: Focus on Hypertension of Developmental Origins.
Biomedicines. 2021 May 31;9(6):623. doi: 10.3390/biomedicines9060623.
10
SMT and TOFT Integrable After All: A Reply to Bizzarri and Cucina.
Acta Biotheor. 2017 Mar;65(1):81-85. doi: 10.1007/s10441-016-9286-z. Epub 2016 Aug 17.
本文引用的文献
1
The Causal-Benefit Model to Prevent Cardiovascular Events.
JACC Adv. 2024 Jan 22;3(3):100825. doi: 10.1016/j.jacadv.2023.100825. eCollection 2024 Mar.
2
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
3
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
Eur Heart J. 2015 Nov 14;36(43):2975-83. doi: 10.1093/eurheartj/ehv340. Epub 2015 Aug 4.
4
Taking a longer term view of cardiovascular risk: the causal exposure paradigm.
BMJ. 2014 May 21;348:g3047. doi: 10.1136/bmj.g3047.
5
An evidence based approach to individualising treatment.
BMJ. 1995 Nov 18;311(7016):1356-9. doi: 10.1136/bmj.311.7016.1356.
Zotero 插件